Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 68 articles: HTML format

Single Articles

March 2024
1. WELLS CR, Pandey A, Moghadas SM, Fitzpatrick MC, et al
   Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
   Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-2451.
   PubMed     Abstract available
   
   
   
2. HUITS R, Grubaugh ND, Libman M, Hamer DH, et al
   Resurgence of Dengue in the Era of Genomic Surveillance and Vaccines.
   Ann Intern Med. 2024 Mar 19. doi: 10.7326/M24-0496.
   PubMed    
   
   
   
3. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
   Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial.
   Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
   PubMed     Abstract available
   
   
   February 2024
4. LAINE C, Qaseem A, Moyer DV
   Putting Adult Vaccine Recommendations Into Action.
   Ann Intern Med. 2024 Feb 13. doi: 10.7326/M24-0242.
   PubMed    
   
   
   
5. CENTOR RM, Tenforde MW, Dawood FS
   Web Exclusive. Annals On Call - Encouraging Influenza Vaccination.
   Ann Intern Med. 2024;177:eA230004.
   PubMed    
   
   
   January 2024
6. ZERBO O, Bartlett J, Fireman B, Lewis N, et al
   Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
   Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-2023.
   PubMed     Abstract available
   
   
   
7. WU Q, Tong J, Zhang B, Zhang D, et al
   Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
   Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
   PubMed     Abstract available
   
   
   November 2023
8. TENFORDE MW, Dawood FS, Ellington SR, Grohskopf LA, et al
   Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine Effectiveness to Acceptance.
   Ann Intern Med. 2023 Nov 28. doi: 10.7326/M23-2802.
   PubMed    
   
   
   September 2023
9. KOTTON CN
   More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus Vaccines for Adults Aged 60 Years and Older.
   Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-2196.
   PubMed    
   
   
   June 2023
10. 
    Correction: Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/L23-0217.
    PubMed    
    
    
    
11. AWAR M, Mylonakis E
    In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0039.
    PubMed     Abstract available
    
    
    
12. AWAR M, Mylonakis E
    In older adults, an AS01(E)-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0038.
    PubMed     Abstract available
    
    
    
13. BAJEMA KL, Berry K, Streja E, Rajeevan N, et al
    Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Ann Intern Med. 2023 Jun 6:M22-3565. doi: 10.7326/M22-3565.
    PubMed     Abstract available
    
    
    May 2023
14. HULME WJ, Williamson E, Horne EMF, Green A, et al
    Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 May 2:M21-4269. doi: 10.7326/M21-4269.
    PubMed     Abstract available
    
    
    March 2023
15. WANG TY, Wahed AS, Morris A, Kreuziger LB, et al
    Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
    Ann Intern Med. 2023 Mar 21. doi: 10.7326/M22-3350.
    PubMed     Abstract available
    
    
    
16. WAN EYF, Yan VKC, Mok AHY, Wang B, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Ann Intern Med. 2023 Mar 14. doi: 10.7326/M22-3057.
    PubMed     Abstract available
    
    
    December 2022
17. 
    Correction: Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2022 Dec 27. doi: 10.7326/L22-0508.
    PubMed    
    
    
    
18. DRYDEN-PETERSON S, Kim A, Kim AY, Caniglia EC, et al
    Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-2141.
    PubMed     Abstract available
    
    
    October 2022
19. ROOZEN GVT, Prins MLM, van Binnendijk R, den Hartog G, et al
    Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
    Ann Intern Med. 2022 Oct 25. doi: 10.7326/M22-2089.
    PubMed    
    
    
    
20. IOANNOU GN, Bohnert ASB, O'Hare AM, Boyko EJ, et al
    Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ann Intern Med. 2022 Oct 11. doi: 10.7326/M22-1856.
    PubMed     Abstract available
    
    
    
21. GODDARD K, Hanson KE, Lewis N, Weintraub E, et al
    Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/M22-2274.
    PubMed    
    
    
    September 2022
22. TAN CY, Chiew CJ, Lee VJ, Ong B, et al
    Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.
    Ann Intern Med. 2022 Sep 13. doi: 10.7326/M22-2042.
    PubMed    
    
    
    August 2022
23. BOTTON J, Jabagi MJ, Bertrand M, Baricault B, et al
    Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Ann Intern Med. 2022 Aug 23. doi: 10.7326/M22-0988.
    PubMed     Abstract available
    
    
    
24. BROPHY JM
    mRNA COVID-19 vaccines were linked to myocarditis at 28 d (0.15 to 10 excess events/100 000 vaccinated persons).
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0057.
    PubMed     Abstract available
    
    
    
25. AISENBERG GM
    In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0056.
    PubMed     Abstract available
    
    
    July 2022
26. FORSTER D
    COVID-19 diagnosis, but not vaccination, was linked to increased risk for immune-mediated neurologic events.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0048.
    PubMed     Abstract available
    
    
    
27. FOLLMANN D, Janes HE, Buhule OD, Zhou H, et al
    Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/M22-1300.
    PubMed     Abstract available
    
    
    May 2022
28. ROSENBLUM HG, Lewis RM, Gargano JW, Querec TD, et al
    Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M21-3798.
    PubMed     Abstract available
    
    
    
29. PERKINS RB, Saslow D, Oliver K
    Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-1309.
    PubMed    
    
    
    
30. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
    Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
    PubMed     Abstract available
    
    
    
31. KRYCHTIUK KA, Newby LK
    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    PubMed     Abstract available
    
    
    
32. GRANWEHR BP
    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    PubMed     Abstract available
    
    
    
33. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    PubMed     Abstract available
    
    
    April 2022
34. KOTTON CN
    Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/M22-1026.
    PubMed    
    
    
    
35. ROTHBERG MB
    Community-Acquired Pneumonia.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/AITC202204190.
    PubMed     Abstract available
    
    
    March 2022
36. ZHENG C, Duffy J, Liu IA, Sy LS, et al
    Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data.
    Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-3023.
    PubMed     Abstract available
    
    
    
37. LARSON EB, Nelson JC
    In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barre syndrome.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0010.
    PubMed     Abstract available
    
    
    
38. SILVESTRI EG, Borzak S
    In patients with MI or high-risk coronary disease, influenza vaccination reduced CV events at 12 mo.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0006.
    PubMed     Abstract available
    
    
    February 2022
39. GAZIT S, Shlezinger R, Perez G, Lotan R, et al
    The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
    PubMed     Abstract available
    
    
    
40. HVIID A, Hansen JV, Thiesson EM, Wohlfahrt J, et al
    Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-2452.
    PubMed     Abstract available
    
    
    
41. KANG M, Yi Y, Li Y, Sun L, et al
    Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-3509.
    PubMed     Abstract available
    
    
    
42. CHANG R
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Another Way That Hospitalists Can Fight COVID-19.
    Ann Intern Med. 2022;175:HO2-HO3.
    PubMed    
    
    
    January 2022
43. TSUN LAI FT, Li X, Peng K, Huang L, et al
    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3700.
    PubMed     Abstract available
    
    
    
44. QASEEM A, Yost J, Etxeandia-Ikobaltzeta I, Forciea MA, et al
    What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3272.
    PubMed     Abstract available
    
    
    
45. SEE I, Lale A, Marquez P, Streiff MB, et al
    Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    Ann Intern Med. 2022 Jan 18. doi: 10.7326/M21-4502.
    PubMed     Abstract available
    
    
    
46. CAILLARD S, Thaunat O, Benotmane I, Masset C, et al
    Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
    Ann Intern Med. 2022 Jan 11. doi: 10.7326/L21-0598.
    PubMed    
    
    
    December 2021
47. IOANNOU GN, Locke ER, O'Hare AM, Bohnert ASB, et al
    COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3256.
    PubMed     Abstract available
    
    
    
48. FAY MP, Hunsberger S, Follmann D
    Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3609.
    PubMed    
    
    
    
49. ANAND S, Montez-Rath ME, Han J, Garcia P, et al
    SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4176.
    PubMed     Abstract available
    
    
    
50. LAINE C, Moyer DV, Cotton D
    COVID-19: Challenging Clinical Questions.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4611.
    PubMed    
    
    
    
51. 
    Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021;174:1780.
    PubMed    
    
    
    November 2021
52. KUMAR D, Ferreira VH, Hall VG, Hu Q, et al
    Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-3480.
    PubMed     Abstract available
    
    
    
53. CHO BH, Weinbaum C, Tsai Y, Koppaka R, et al
    Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season : A Retrospective Cohort Study.
    Ann Intern Med. 2021 Nov 16. doi: 10.7326/M21-1550.
    PubMed     Abstract available
    
    
    
54. SARPATWARI A, Pandya A, Hyle EP, Persad G, et al
    COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/M21-3927.
    PubMed    
    
    
    
55. UYEKI TM
    Influenza.
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/AITC202111160.
    PubMed     Abstract available
    
    
    
56. MAKI DG
    Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available
    
    
    
57. GRANWEHR BP
    BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available
    
    
    
58. SACKS HS
    The Novavax vaccine had 90% efficacy against COVID-19 >/=7 d after the second dose.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed     Abstract available
    
    
    
59. DORFMAN AL, Murthy VL
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Myocarditis After Vaccination for SARS-CoV-2.
    Ann Intern Med. 2021;174:HO2-HO3.
    PubMed    
    
    
    October 2021
60. HIMMELSTEIN J, Himmelstein DU, Woolhandler S, Dickman S, et al
    COVID-19-Related Care for Hispanic Elderly Adults With Limited English Proficiency.
    Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-2900.
    PubMed    
    
    
    
61. NOVAZZI F, Taborelli S, Baj A, Focosi D, et al
    Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing.
    Ann Intern Med. 2021 Oct 19. doi: 10.7326/M21-3486.
    PubMed    
    
    
    
62. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
    Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
    PubMed    
    
    
    
63. LAINE C, Cotton D, Moyer DV
    COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-3840.
    PubMed    
    
    
    
64. DELANEY SW, Essien UR, Navathe A
    Disparate Impact: How Colorblind Policies Exacerbate Black-White Health Inequities.
    Ann Intern Med. 2021;174:1450-1451.
    PubMed    
    
    
    September 2021
65. CURTIS JR, Cofield SS, Bridges SL Jr, Bassler J, et al
    The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
    Ann Intern Med. 2021 Sep 28. doi: 10.7326/M20-6928.
    PubMed     Abstract available
    
    
    
66. REIF J, Heun-Johnson H, Tysinger B, Lakdawalla D, et al
    Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study.
    Ann Intern Med. 2021 Sep 21. doi: 10.7326/M21-2239.
    PubMed     Abstract available
    
    
    
67. MOGHADAS SM, Sah P, Shoukat A, Meyers LA, et al
    Population Immunity Against COVID-19 in the United States.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/M21-2721.
    PubMed     Abstract available
    
    
    August 2021
68. PALTIEL AD, Schwartz JL
    Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-2965.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.